Gyre Therapeutics (GYRE) Return on Capital Employed (2011 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Return on Capital Employed of 0.1% for Q1 2026, down 964.0% year-over-year from 0.01% in Q1 2025, and down 101.23% quarter-over-quarter from 7.95% in Q4 2025.
Gyre Therapeutics (GYRE) Return on Capital Employed (2011 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Return on Capital Employed for 16 consecutive years, with 0.1% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 964.0% year-over-year to 0.1%; the TTM figure through Mar 2026 stood at 0.1% (down 964.0% YoY), while the FY2025 annual figure was 9.01%, down 692.0% from the prior year.
- Return on Capital Employed retreated to 0.1% in Q1 2026 per GYRE's latest filing, from 7.95% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 68.07% in Q1 2023 and bottomed at 230.48% in Q1 2022.
- Historically, Return on Capital Employed has averaged 32.25% across 5 years, with a median of 7.52% in 2025.
- On a YoY basis, Return on Capital Employed climbed as much as 29855 bps in 2023 and fell as far as 17577 bps in 2023.
- Gyre Therapeutics' Return on Capital Employed stood at 20.16% in 2022, then sank by 872 bps to 155.61% in 2023, then jumped by 110 bps to 15.28% in 2024, then tumbled by 48 bps to 7.95% in 2025, then tumbled by 101 bps to 0.1% in 2026.
- Business Quant data shows GYRE's Return on Capital Employed at 0.1% in Q1 2026, 7.95% in Q4 2025, and 8.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -10.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.97% |
| Mar 31, 2026 | -0.10% |
| Dec 31, 2025 | 7.95% |
| Sep 30, 2025 | 8.59% |
| Jun 30, 2025 | 7.52% |
| Mar 31, 2025 | 9.54% |
| Dec 31, 2024 | 15.28% |
| Sep 30, 2024 | -70.25% |
| Jun 30, 2024 | -63.84% |
| Mar 31, 2024 | -65.96% |
| Dec 31, 2023 | -155.61% |
| Sep 30, 2023 | 20.67% |
| Jun 30, 2023 | -125.11% |
| Mar 31, 2023 | 68.07% |
| Dec 31, 2022 | 20.16% |
| Sep 30, 2022 | 20.43% |
| Jun 30, 2022 | -15.15% |
| Mar 31, 2022 | -230.48% |
| Dec 31, 2021 | -166.04% |
| Sep 30, 2021 | -118.53% |